Gabapentin Capsule
Product Images NDC 45865-194

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 45865-194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

194 (45865 194)

Label for Gabapentin capsules 300 mg, generic for Neurontin, by ScieGen Pharm. Inc. The label states the capsules are yellow, oblong, with a unit size of 180. It includes the NDC 45865-0194-60 and indicates a quantity of 60 capsules. The label also mentions potential dizziness or drowsiness and advises avoiding alcohol.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an 8-week period, comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, starting from baseline to week 8, including a 4-week dose titration and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. The graph shows a decrease in pain score for Gabapentin use over time compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled "Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" comparing placebo (PBO) to Gabapentin (GBP) at different doses across two studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance markers indicate p-values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

An illustration of the creatinine clearance (CLCr) equation used in clinical settings, displaying the formula involving age, weight, serum creatinine, and adjustment for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino group and a carboxylic acid group, representing its molecular arrangement.*

FDA Label Image

Image-09 (Image 09)

A scatter plot comparing percentage difference by daily dose in mg across three studies labeled 'a,' 'b,' and 'c.' The x-axis shows daily doses from 600 to 1800 mg, and the y-axis shows percentage difference from 2% to 22%. The graph displays markers for each study at dose points 600, 900, 1200, and 1800 mg, with study 'a' showing the highest percentage difference at 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.